【摘要】：桑多斯虎眼萬年青(Ornithogalum saundersiae Baker),為天門冬科(Asparagaceae)虎眼萬年青屬球根狀植物,原產(chǎn)于南歐和南非地區(qū),近年來,被廣泛培育為花園植物。從該種植物已發(fā)表的科學(xué)研究中發(fā)現(xiàn),以O(shè)SW-1為代表的膽甾烷型留體皂苷類化合物具有顯著的藥理活性,我們從中得到啟發(fā)對(duì)該種植物進(jìn)行進(jìn)一步的植物化學(xué)方面研究,因此本碩士學(xué)位論文主要開展了采用多種不同的色譜分離手段相結(jié)合對(duì)桑多斯虎眼萬年青乙醇提取物的正丁醇萃取液中的甾體皂苷類化合物進(jìn)行了分離純化和結(jié)構(gòu)鑒定,并在人體腫瘤細(xì)胞毒性藥理模型和LPS誘導(dǎo)原代小鼠腹腔巨噬細(xì)胞炎癥因子NO生成模型上,對(duì)已經(jīng)分離鑒定的化合物進(jìn)行了初步的藥理活性篩選。結(jié)果表明,從桑多斯虎眼萬年青(O.saundersiae Baker)乙醇提取物的正丁醇部分已經(jīng)分離并鑒定了 26個(gè)化合物(1-26),其中19個(gè)新化合物(1-19)。這26個(gè)化合物分別為:(22S)-3β-[(β-D-glucopyranosyl-(1→2)-β-D-glucopyranosyl)oxy]-1 1α22-dihydroxycholest-5,24-dien-16β-yl α-L-rhamnopyranoside(1),(22S)-3β-[(α-L-rhamnopyranosyl-(1→2)-β-D-glucopyranosyl)oxy]-1 1α,22-dihydroxycholest-5,24-dien-16β-yl α-L-rhamnopyranoside(2),(22S)-3β-[(α-L-rhamnopyranosyl-(1→2)-β-D-glucopyranosyl-(1→6)-β-D-glucopyranosyl)oxy]-22-hydroxycholest-5,24-dien-1 6β-yl α-L-rhamnopyranoside(3),(22S)-3β-[β-D-glucopyranosyl-(1→6)-β-D-glucopyranosyl-(1→6)-β-D-glucopyranosyl)oxy]-22-hydroxycholest-5,24-dien-16β-ylα-L-rhamnopyranoside(4),(22S)-3β-[(α-L-rhamnopyranosyl-(1→2)-β-D-glucopyranosyl)oxy]-1 1α,22-dihydroxycholest-5-en-16β-yl α-L-rhamnopyranoside(5),(22S)-3β-[β-D-glucopyranosyl-(1→6)-β-D-glucopyranosyl)oxy]-1 1α,22-dihydroxycholest-5-en-16β-yl α-L-rhamnopyranoside(6),(22S)-1β-[(α-L-rhamnopyranosyl)oxy]-3β-[(β-D-glucopyranosyl)oxy]-22-hydroxycholest-5,24-dien-16β-yl α-L-rhamnopyranoside(7),(22S)-1β-[β-D-glucopyranosyl)oxy]-3β-[(β-D-glucopyranosyl)oxy]-22-hydroxycholest-5,24-dien-16β-yl α-L-rhamnopyranoside(8),3-[(α-L-rhamnopyranosyl-(1→2)-β-D-gluc opyranosyl-(1→2)-β-D-glucopyranosyl)oxy]-16,23-epoxy-1 1α,22-dihydroxy-23-(2-methyl-1-propenyl)-(3β,16β,22R,23S)-yl cholestane triglycoside(9),3-[(β-D-glucopyranosyl-(1→2)-β-D-glucopyranosy 1)oxy]-1623-epoxy-22-hydroxy-23-(2-methyl-1-propenyl)-(3β,16β,22R,23S)-yl cholestane diglycoside(10),3-[(α-L-rhamnopyranosyl-(1→2)-β-D-glucopyranosyl-(1→2)-β-D-glucopyranosyl-(1-→6)-β-D-glucopyranosyl)oxy]-16,23-epoxy-23-hydroxy-22-(2-methyl-1-propenyl)-(3β,16β,22S,23R)-24-norchol-5-en-18-al(11),3-[(α-L-rhamnopyranosy l-(1→2)-β-D-glue opyranosyl→2)-β-D-glue opyranosy 1)oxy]-16,23-e poxy-23-hydroxy-22-(2-methyl-1-propenyl)-(3β,16β,22S,23R)-24-norc ho l-5-en-18-oic acid(12),(23E)-cholest-5523-dien-1β,3β,16β25-tetrol 1-O-ββ-D-glucopyranoside 16-O-α-L-arabinopyranoside(13),(23E)-cholest-5,23-dien-1β,3β,16β,25-tetrol 1-O-β-D-glucopyranos ide 16-0-(3-0-3,4,5-trimethoxy benzoy l-α-L-arabinopyranoside)(14),(23E)-cholest-5,23-dien-1β,3β,16β,25-tetrol 1-O-β-D-gluc opyranos y l-(1→6)-)β-D-glucopyranos ide 16-0-(3-0-3,4,5-tr imethoxybe nzoy 1-α-L-arabinopyranoside)(15),(23E)-cholest-5,23-dien-1β,3β,16β-trio 1-25-O-n-butyl 1-O-β-D-glucopyranosyl-(1→6)-)β-D-glucopyranoside 16-0-(3-0-3,4,5-trimethoxybenzoy l-α-L-arabinopyranos ide)(16),22-[(β-D-glucopyranosyl)oxy]-16,23-epoxy-1,3,1 1-trihydroxy-23-(2-methyl-1-propenyl)-(1α,3α,11α,16β,22R,23S)-yl cholestane glycoside(17),3β-[(β-D-glucopyranosyl-(1→6)-β-D-glucopyranosyl)oxy]-16β-[(β-D-glucopyranosyl-(1→6)-D-gluc opyranosy l-(1→4)-β-D-xylopyranosy l-(1 3)-2-O-acety l-α-L-arabinopyranosy l)oxy]-17α-hydroxy-cholest-5-en-22-one(18),cholest-5-en-16,18-epoxy-20-[5',5'-dimethylfuran-2'(5'H-one]-3β,18α-dihydroxy 3-O-α-L-rhamnopyranosyl-(1→2)-β-D-glucopyranosyl-(12)-β-D-glucopyranoside(19),(22S)-3β,11α,22-trihydroxycholest-5,24-dien-16β-ylα-L-rhamnopyranoside(20),(22S)-3β-[(β-D-glucopyranosyl)oxyl]-11α,22-dihydroxycholest-5,24-dien-116-yl α-L-rhamnopyranoside(21),(22S)-3β-[(β-D-glucopyranosyl)oxyl]-11α,22-dihydroxycholest-5-en-16β-yl α-L-rhamnopyranoside(22),3-[(α-L-rhamnopyranosyl-(1→2)-β-D-glucopyranosyl-(1→2)-β-D-glucopyranosylDoxy]-16,23-epoxy-22-hydroxy-23-(2-methyl-1-propenyl)-(3β,16β,22R,23S)-yl cholestane triglycoside(23),3-[(α-L-rhamnopyranosyl-(1→2)-β-D-glucopyranosyl-(1→2)-β-D-glucopyranosyl)oxy]-16,23-epoxy-23-hydroxy-22-(2-methy l-1-propenyl)-(3β,16β,22S,23R)-24-norchol-5-en-18-al(24),3,4,5-0-trioxymethyl benzoate(25),N-butyl phthalate(26)。以上化合物的藥理活性篩選結(jié)果顯示,化合物3在劑量為1×10-5M時(shí)對(duì)人乳腺癌細(xì)胞MCF-7有一定的細(xì)胞毒作用(IC50值為0.20μM,陽性對(duì)照藥紫杉醇的IC50值為19.9 nM)。化合物12在劑量為1 X 10-5 M時(shí)對(duì)LPS誘導(dǎo)原代小鼠腹腔巨噬細(xì)胞釋放的炎癥因子NO具有良好的抑制作用(抑制率為56.81%,陽性對(duì)照藥為地塞米松的抑制率為95.74%)。
【學(xué)位授予單位】：北京協(xié)和醫(yī)學(xué)院
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2019
【分類號(hào)】：R284.1;R285
，

本文編號(hào)：2706997